Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03616184 · ClinicalTrials.gov registry record · Phase 2
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
A Phase 2 study of Graft-versus-host Disease (GVHD), sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 5
- Study locations
NCT03616184 is a Phase 2 study of Graft-versus-host Disease (GVHD) that has completed, run by University of Nebraska. The registered enrollment target is 49 participants, below the 379-participant average among 3 other Graft-versus-host Disease (GVHD) trials with a reported enrollment target (87% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03616184, a Phase 2 study of Graft-versus-host Disease (GVHD), has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of the study is to examine the efficacy of ruxolitinib in patients with sclerotic chronic graft-versus-host disease (GVHD).
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (5)
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Florida
- Moffitt Cancer Center - Tampa
Nebraska
- University of Nebraska Medical Center - Omaha
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2023-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03616184
The ClinicalTrials.gov registry entry for NCT03616184 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 3 other Graft-versus-host Disease (GVHD) trials with a reported enrollment target (87% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft-versus-host Disease (GVHD) appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT03616184 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Florida, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03616184 about?
NCT03616184 is a clinical study titled "Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids". The primary objective of the study is to examine the efficacy of ruxolitinib in patients with sclerotic chronic graft-versus-host disease (GVHD).
What is the current status of trial NCT03616184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-09-05. Estimated completion is 2023-06-12.
What conditions does trial NCT03616184 study?
This clinical trial studies the following conditions: Graft-versus-host Disease (GVHD).
What interventions are being tested in trial NCT03616184?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT03616184?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03616184 being conducted?
This trial has 5 study locations across Florida, Nebraska, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-versus-host Disease (GVHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
RECRUITING · Phase 3
-
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.